Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5702007 | 0.85 | ALDH1A1 (0.31) | ALDH1A1CNR1CNR2 | |
| SCHEMBL9419512 | 0.85 | ALDH1A1 (0.31) | ALDH1A1CNR1CNR2 | |
| SCHEMBL10670026 | 0.84 | LMNA (0.48) | LMNAALDH1A1CNR1CNR2TSHR | |
| SCHEMBL10444993 | 0.84 | LMNA (0.48) | LMNAALDH1A1CNR1CNR2TSHR | |
| SCHEMBL28269409 | 0.84 | LMNA (0.48) | LMNAALDH1A1CNR1CNR2TSHR | |
| SCHEMBL7598357 | 0.83 | CNR2 (0.44) | LMNAALDH1A1CNR1CNR2TSHR | |
| SCHEMBL7598483 | 0.83 | CNR2 (0.44) | LMNAALDH1A1CNR1CNR2TSHR | |
| SCHEMBL6744916 | 0.81 | ALDH1A1 (0.32) | ALDH1A1CNR1CNR2TSHR | |
| SCHEMBL13612346 | 0.80 | LMNA (0.34) | LMNA | |
| SCHEMBL4130405 | 0.79 | CNR1 (0.44) | LMNAALDH1A1CNR1CNR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| EP-1532263-B1 | METHOD FOR HYDROLYSING CAROTENOIDS ESTERS | SUNGENE GMBH & CO KGAA (DE) | 2006-10-11 | — | — | EP | disclosed |
| EP-1532263-A2 | METHOD FOR HYDROLYSING CAROTENOIDS ESTERS | Sungene GmbH & Co. KGaA (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004022765-A2 | METHOD FOR HYDROLYSING CAROTENOIDS ESTERS | SUNGENE GMBH & CO. KGAA (DE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | LMNA 3334/4885ALDH1A1 4444/4885CNR1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.